Skip to main content
Europe

BioWin's range of European projects continues to grow

After Magia and S3martMed, we now present SAFE N MEDTECH and NEMS4Bio

The new S3martMed project funded by the COSME programme kicked off in Lyon, France on the 5th and 6th of November 2018. The project’s 5 partner clusters - Lyonbiopole (Auvergne Rhônes-Alpes), BioWin (Wallonia), BioPmed (Piedmont), GAPR-Medsilesia (Upper Silesia) and Bioregion STERN (Baden Wurttemberg) - are all involved in Platform S3 and have decided to set up a new partnership, the European Strategic Cluster Partnership (ESCP) for Smart Specialisation Investments in Medical Technologies, to facilitate interregional and intersectoral collaboration between European clusters and their medtech SME members by setting up a cluster partnership.

The goal of this new project is to identify the skills of each region, but also their financial, business or regulatory needs, to help sustain the sector’s SMEs. S3MARTMED has announced an action plan catering to these SMEs that includes:

• Organizing inter-regional B2B and C2C networks involving SMEs, technology centres and key players in the partners’ regions

• Organizing activities specifically for SMEs in the medtech sector

• Assessing the companies’ readiness and their financial situation, and defining potential investment plans as pilot cases

The aim of the S3MARTMED project, which will span two years, is to “speak with one voice”.

SAFE N MEDTECH, a new European H2020 NMBP (Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing) medtech project, has just been launched. BioWin has joined this project as a third party through the Council of European BioRegions (CEBR). This is an opportunity to integrate a future hub of more than 30 medtech partners. BioWin will contribute to the hub’s dissemination and creation.

SAFE-N-MEDTECH will build an innovative open access platform providing reference laboratories and companies with the capabilities, know-how, networks and services needed for developing, testing, evaluating, optimizing and marketing nanotechnology and diagnostic medical devices throughout the products’ entire lifecycle.

This platform will give SMEs, healthcare providers and industries a novel, multi-disciplinary, market-driven approach based on in-depth understanding and knowledge of materials, property, advanced uses and applications in the medtech sector.

BioWin's range of European projects continues to grow

On November 12th and 13th, BioWin attended the Vanguard Initiative New Nano Enabled Products plenary meeting in Bologna (Italy). Vanguard Initiative is a European network of 30 industrial regions that aims to foster interregional partnerships and support regional clusters and ecosystems with a focus on smart specializations in key areas for changing and emerging industries. Nanotechnology is one of the five thematic pilot projects. Wallonia’s DG06 is part of this network.

At the meeting, three demo cases were presented: Nano Wires for ICT and Energy Applications; Nano-Enabled Printed Electronics and Nano-Enabled Micro Systems for Bio Analysis (NeMs4Bio).

BioWin is to invest in NeMs4Bio, a demo case that aims to meet the challenges of incorporating microfluidics in various fields such as medtech and biomanufacturing. Seven regions are involved in this demo case: Flanders, East Netherlands, Emilia Romagna, Navarra, Tampere and Auvergne Rhone-Alpes. The project is led by IMEC (Flanders).

The next stages of the partnership will be:

• Ascertaining each region’s exact skills

• Facilitating technical discussions among experts in each region on the potential synergies and complementarities between regions

• Laying the groundwork to connect specific facilities and stakeholders

Eventually this demo case will form ties between the regions, establish companies’ needs and influence future European funding in this field.